KYMERA THERAPEUTICS I

Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 Apr 2022 12:02:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

02 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

24 Feb 2022 06:00:03 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences

25 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors

18 Jan 2022 07:00:05 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company

10 Jan 2022 06:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day

16 Dec 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations

06 Dec 2021 07:00:03 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

30 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021

17 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

12 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update

10 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting

04 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences

01 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

27 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th

20 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

13 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

06 Aug 2021 06:00:01 By Nasdaq GlobeNewswire